WO1998055602A1 - Criblage d'inhibiteurs de la kinase liee au phosphatidilynositol - Google Patents

Criblage d'inhibiteurs de la kinase liee au phosphatidilynositol Download PDF

Info

Publication number
WO1998055602A1
WO1998055602A1 PCT/US1998/011420 US9811420W WO9855602A1 WO 1998055602 A1 WO1998055602 A1 WO 1998055602A1 US 9811420 W US9811420 W US 9811420W WO 9855602 A1 WO9855602 A1 WO 9855602A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
wortmannin
kinase
mtor
phas
Prior art date
Application number
PCT/US1998/011420
Other languages
English (en)
Other versions
WO1998055602A9 (fr
Inventor
Robert T. Abraham
Jann N. Sarkaria
Original Assignee
Mayo Foundation For Medical Education And Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation For Medical Education And Research filed Critical Mayo Foundation For Medical Education And Research
Priority to AU79535/98A priority Critical patent/AU7953598A/en
Priority to CA002292540A priority patent/CA2292540A1/fr
Priority to EP98930061A priority patent/EP0990028A4/fr
Publication of WO1998055602A1 publication Critical patent/WO1998055602A1/fr
Publication of WO1998055602A9 publication Critical patent/WO1998055602A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)

Abstract

Cette invention concerne un procédé permettant d'identifier un composé qui inhibe l'activité de phosphorylation d'un polypeptide de kinase apparenté au phosphoinositide 3-kinase; ainsi que des anticorps présentant une affinité de liaison spécifique pour un conjugué comprenant du wortmannin.
PCT/US1998/011420 1997-06-06 1998-06-05 Criblage d'inhibiteurs de la kinase liee au phosphatidilynositol WO1998055602A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU79535/98A AU7953598A (en) 1997-06-06 1998-06-05 Screening for phosphatidylinositol related-kinase inhibitors
CA002292540A CA2292540A1 (fr) 1997-06-06 1998-06-05 Criblage d'inhibiteurs de la kinase liee au phosphatidilynositol
EP98930061A EP0990028A4 (fr) 1997-06-06 1998-06-05 Criblage d'inhibiteurs de la kinase liee au phosphatidilynositol

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4886997P 1997-06-06 1997-06-06
US60/048,869 1997-06-06

Publications (2)

Publication Number Publication Date
WO1998055602A1 true WO1998055602A1 (fr) 1998-12-10
WO1998055602A9 WO1998055602A9 (fr) 1999-04-08

Family

ID=21956893

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/011420 WO1998055602A1 (fr) 1997-06-06 1998-06-05 Criblage d'inhibiteurs de la kinase liee au phosphatidilynositol

Country Status (4)

Country Link
EP (1) EP0990028A4 (fr)
AU (1) AU7953598A (fr)
CA (1) CA2292540A1 (fr)
WO (1) WO1998055602A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348311B1 (en) 1999-02-10 2002-02-19 St. Jude Childre's Research Hospital ATM kinase modulation for screening and therapies
US6387640B1 (en) 1999-02-10 2002-05-14 St. Jude Children's Research Hospital ATM kinase modulation for screening and therapies
AU783332B2 (en) * 2000-08-11 2005-10-13 Uni-Charm Corporation Disposable undergarment
US7049313B2 (en) 2002-02-25 2006-05-23 Kudos Pharmaceuticals Ltd. ATM inhibitors
US7105518B2 (en) 2001-08-14 2006-09-12 Cancer Research Technology Limited Thiopyrane-4-ones as DNA protein kinase inhibitors
US7138236B1 (en) 1997-07-16 2006-11-21 Kudos Pharmaceuticals Limited Interactions of ATM, ATR or DAN-PK with p53
US7226918B2 (en) 2001-08-14 2007-06-05 Cancer Research Technology Limited DNA-PK inhibitors
US7402607B2 (en) 2004-09-20 2008-07-22 Kudos Pharmaceuticals Limited DNA-PK inhibitors
US7429660B2 (en) 2003-08-13 2008-09-30 Kudos Pharmaceuticals Limited ATM inhibitors
WO2009047567A1 (fr) * 2007-10-10 2009-04-16 University Of Sheffield Essai pour identifier des agents qui inhibent les voies atr et/ou dna-pk
US7642254B2 (en) 2005-02-09 2010-01-05 Kudos Pharmaceuticals Limited ATM inhibitors
US7696203B2 (en) 2005-04-15 2010-04-13 Kudos Pharmaceuticals Limited DNA-PK inhibitors
US9644037B2 (en) 2013-10-18 2017-05-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that specifically bind ataxia telangiectasia-mutated and RAD3-related kinase phosphorylated at position 1989 and their use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5151360A (en) * 1990-12-31 1992-09-29 Biomembrane Institute Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation
US5466716A (en) * 1990-12-31 1995-11-14 The Biomembrane Institute Liposomal trimethylsphingosine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5151360A (en) * 1990-12-31 1992-09-29 Biomembrane Institute Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation
US5466716A (en) * 1990-12-31 1995-11-14 The Biomembrane Institute Liposomal trimethylsphingosine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0990028A4 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138236B1 (en) 1997-07-16 2006-11-21 Kudos Pharmaceuticals Limited Interactions of ATM, ATR or DAN-PK with p53
US6387640B1 (en) 1999-02-10 2002-05-14 St. Jude Children's Research Hospital ATM kinase modulation for screening and therapies
US6348311B1 (en) 1999-02-10 2002-02-19 St. Jude Childre's Research Hospital ATM kinase modulation for screening and therapies
AU783332B2 (en) * 2000-08-11 2005-10-13 Uni-Charm Corporation Disposable undergarment
US7674823B2 (en) 2001-08-14 2010-03-09 Cancer Research Technology Limited DNA-PK inhibitors
US7105518B2 (en) 2001-08-14 2006-09-12 Cancer Research Technology Limited Thiopyrane-4-ones as DNA protein kinase inhibitors
US7226918B2 (en) 2001-08-14 2007-06-05 Cancer Research Technology Limited DNA-PK inhibitors
US7049313B2 (en) 2002-02-25 2006-05-23 Kudos Pharmaceuticals Ltd. ATM inhibitors
US7429660B2 (en) 2003-08-13 2008-09-30 Kudos Pharmaceuticals Limited ATM inhibitors
US7402607B2 (en) 2004-09-20 2008-07-22 Kudos Pharmaceuticals Limited DNA-PK inhibitors
US7732483B2 (en) 2004-09-20 2010-06-08 Kudos Pharmaceuticals Limited DNA-PK inhibitors
US7642254B2 (en) 2005-02-09 2010-01-05 Kudos Pharmaceuticals Limited ATM inhibitors
US7696203B2 (en) 2005-04-15 2010-04-13 Kudos Pharmaceuticals Limited DNA-PK inhibitors
WO2009047567A1 (fr) * 2007-10-10 2009-04-16 University Of Sheffield Essai pour identifier des agents qui inhibent les voies atr et/ou dna-pk
US9644037B2 (en) 2013-10-18 2017-05-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that specifically bind ataxia telangiectasia-mutated and RAD3-related kinase phosphorylated at position 1989 and their use

Also Published As

Publication number Publication date
EP0990028A1 (fr) 2000-04-05
CA2292540A1 (fr) 1998-12-10
EP0990028A4 (fr) 2000-09-27
WO1998055602A9 (fr) 1999-04-08
AU7953598A (en) 1998-12-21

Similar Documents

Publication Publication Date Title
US5352660A (en) Method for assaying for a substance that affects a SH2-phosphorylated ligand regulatory system
Reuther et al. Association of the protein kinases c-Bcr and Bcr-Abl with proteins of the 14-3-3 family
Millward et al. Calcium regulation of Ndr protein kinase mediated by S100 calcium‐binding proteins
DerMardirossian et al. Phosphorylation of RhoGDI by Pak1 mediates dissociation of Rac GTPase
Diekmann et al. Rac GTPase interacts with GAPs and target proteins through multiple effector sites.
Behrend et al. Interaction of casein kinase 1 delta (CK1δ) with post-Golgi structures, microtubules and the spindle apparatus
She et al. Wiskott-Aldrich syndrome protein is associated with the adapter protein Grb2 and the epidermal growth factor receptor in living cells.
Geng et al. Kinase-independent function of cyclin E
Kazlauskas et al. Phosphorylation of the PDGF receptor beta subunit creates a tight binding site for phosphatidylinositol 3 kinase.
Kowluru et al. Localization and characterization of the mitochondrial isoform of the nucleoside diphosphate kinase in the pancreatic β cell: evidence for its complexation with mitochondrial succinyl-CoA synthetase
Hu et al. Interaction of phosphatidylinositol 3-kinase-associated p85 with epidermal growth factor and platelet-derived growth factor receptors
Auvinen et al. Ornithine decarboxylase-and ras-induced cell transformations: reversal by protein tyrosine kinase inhibitors and role of pp130CAS
Pietromonaco et al. Association of 14-3-3 proteins with centrosomes
EP0990028A1 (fr) Criblage d'inhibiteurs de la kinase liee au phosphatidilynositol
Moyers et al. The sites of phosphorylation by protein kinase C and an intact SH2 domain are required for the enhanced response to β-adrenergic agonists in cells overexpressing c-src
Ulrich et al. Specific TrkA survival signals interfere with different apoptotic pathways
Cha et al. Phosphorylation regulates nucleophosmin targeting to the centrosome during mitosis as detected by cross-reactive phosphorylation-specific MKK1/MKK2 antibodies
EP0759986B1 (fr) Diagnostics de cancers dus a des cellules exprimant la proteine crkl phosphorylee sur tyrosine
Ando et al. Enhanced insulin-induced mitogenesis and mitogen-activated protein kinase activities in mutant insulin receptors with substitution of two COOH-terminal tyrosine autophosphorylation sites by phenylalanine.
US6383734B1 (en) Method to determine inhibition of PAK3 activation of Raf-1
US7087392B2 (en) Antiproliferative SgK reagents and methods
Reilly et al. A novel role for farnesyl pyrophosphate synthase in fibroblast growth factor-mediated signal transduction
Lewis et al. Ca2+/calmodulin-dependent protein kinase mediates the phosphorylation of CD44 required for cell migration on hyaluronan
US5955259A (en) Method for assessing modulation of potassium ion channel activity
Roche et al. The catalytic subunit of phosphatidylinositol 3-kinase is a substrate for the activated platelet-derived growth factor receptor, but not for middle-T antigen-pp60c-src complexes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/7-7/7, DRAWINGS, REPLACED BY NEW PAGES 1/7-7/7; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2292540

Country of ref document: CA

Ref country code: CA

Ref document number: 2292540

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 79535/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998930061

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1999502813

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1998930061

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09445481

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 1998930061

Country of ref document: EP